INVENTION/PATENT APPLICATION ASSIGNMENT FROM INVENTOR(S) TO COMPANY

WHEREAS I/WE Dr. Wolfgang Richter, inventor, and a citizen of Germany, and I, Dr. Lutz WEBER, inventor, and a citizen of Germany, (hereinafter referred as "Assignors") have invented certain new and useful improvements in Thia-Epothilone Derivatives, as set forth in an application for United States Letters Patent, entitled the same, for which an International Application was filed on November 28, 2003, Application No. PCT/EP 2003/013412.

AND WHEREAS, R&D-Biopharmaceuticals GmbH, a corporation of the State of Germany and having an address of Am Klopferspitz 19a, 82152 Martinsried, Germany, hereinafter referred to as assignee, is desirous of acquiring the entire right, title and interest in and to said invention and in and to any and all Letters Patent of the United States and foreign countries that may be obtained therefor,

NOW, THEREFORE, in consideration of One Dollar (\$1.00) and other good and sufficient consideration, the receipt of which is hereby acknowledged, Assignors have sold, assigned, transferred and set over, and by these presents do sell, assign, transfer and set over, unto Assignee, its successors, legal representatives and assigns, the entire right, title and interest in and to the above-mentioned inventions and application for Letters Patent, and in and to any and all direct and indirect divisions, continuations and continuations-in-part of said application, and any and all Letters Patent in the United States and all foreign countries which may be granted therefore and thereon, and reissues, reexaminations and extensions of said Letters Patent, and all rights under the International Convention for the Protection of Industrial Property, the same to be held and enjoyed by Assignee, for its own use and benefit and the use and benefit of its successors, legal representatives and assigns, to the full end of the term or terms for which Letters Patent may be granted and/or extended, as fully and entirely as the same would have been held and enjoyed by Assignors, had this sale and assignment not been made.

AND for the same consideration, Assignors hereby represent and warrant to Assignee, its successors, legal representatives and assigns, that, at the time of execution and delivery of these presents, except for any rights, titles and/or interests that have arisen to Assignee under law or that have already been transferred to Assignee, Assignors are the sole and lawful owners of the entire right, title and interest in and to the said inventions and application for Letters Patent above-mentioned, and that the same are unencumbered and that Assignors have good and full right and lawful authority to sell and convey the same in the manner herein set forth.

AND for the same consideration, Assignors hereby covenant and agree to and with Assignee, its successors, legal representatives and assigns, that Assignors will sign all papers and documents, take all lawful oaths and do all acts necessary or required to be done for the procurement, maintenance, enforcement and defense of any Letters Patent and applications for Letters Patent for said inventions, without charge to Assignee, its successors, legal representatives and assigns, whenever counsel of Assignee, or counsel of its successors, legal representatives and assigns, shall advise: that any proceeding in connection with said inventions, or said Patent application for Letters Patent, or any proceeding in connection with any Letters Patent or applications for Letters Patent for said inventions in any country, including but not limited to interference proceedings, is lawful and desirable; or, that any division, continuation or continuation-in-part of any application for Letters Patent, or any reissue, reexamination or extension of any Letters Patent, to be obtained thereon, is lawful and desirable.

AND Assignors hereby request the Commissioner of Patent and Trademarks to issue said Letters Patent of the United States to Assignee, as Assignee of said inventions and the Letters Patent to be issued thereon, for the sole use and benefit of Assignee, its successors, legal representatives and assigns.

AND Assignors hereby grant the following individuals the power to insert on this Assignment any further identification which may be necessary or desirable in order to comply with the rules of the United States Patent and Trademark Office for recordation of this document:

EDWARDS & ANGELL, LLP

All practitioners at Customer Number 21874

AND Assignors acknowledge an obligation of assignment of this invention to Assignee at the time the invention was made.

Dated this 3 day of	May 2005	Wolfen Ridt
		Dr. Wolfgang Rechter
3	May	S. Midre
Date		Witness
Dated this day of	5	
		Dr. Lutz WEBER
4.	May	2, Lalls
Date		Witness

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being transmitted by facsimile to the Palent and Trademark Office, facsimile no. (571) 273-0140, on the date shown below.

Dated: July 22 2009

Signature: Mun

. DiCelie Rejus SIGIS

ASSIGNMENT

WHEREAS, R&D-Biopharmaceuticals GmbH, a corporation organized under and pursuant to the laws of Germany having its principal place of business at Am Klopferspitz 19, 82152 Martinsried, Germany (hereinafter referred to as Assignor), is the sole and exclusive owner, by assignment, of the Patent Application listed in Schedule A; and

WHEREAS, Dr. Wolfgang Richter, an individual and citizen of Germany, residing at Leharstr. 35, 81243 Munich, Germany, Gesellschaft fuer Biotechnologische Forschung mbH (GBF), a Corporation organized under and pursuant to the laws of Germany having its principal place of business at Mascheroder Weg 1, 38124 Braunschweig, Germany, (hereinafter referred to as Assignees), are desirous of acquiring the right, title and interest in, to and under said Patent Application and the invention covered thereby;

NOW, THEREFORE, in consideration of and in exchange for the sum of One Dollar (\$1.00) and other good and valuable consideration, receipt of which is hereby acknowledged, the said Assignor has sold, assigned, transferred and set over, and does hereby sell, assign, transfer and set over to the said Assignees, the entire right, title and interest for the United States of America and all other countries in and to said applications for all original, divisional, continuation, continuation-in-part, substitute or reissue applications and patents applied for or granted therefore in the United States of America and all other countries on the attached list of Schedule A, and the Commissioner of Patents and Trademarks is hereby authorized and requested to issue all patents on Schedule A to said Assignees herein, as Assignees of the entire interest therein; and the undersigned for itself and its legal representatives, heirs and assigns does hereby agree and covenant without further remuneration, to execute and deliver all divisional, continuation, continuation-in-part, reissue and other applications for Letters Patent and all assignments thereof to said Assignees or their assigns, to communicate to said Assignees or its representatives all facts known to the

communicate to said Assignees or its representatives all facts known to the undersigned respecting said invention listed on *Schedule A* whenever requested, to testify in any interferences or other legal proceedings in which said application or patent may become involved, to sign all lawful papers, make all rightful oaths, and do generally everything necessary to aid Assignees, its successors, assigns and nominees to obtain patent protection for said invention listed on *Schedule A* in the United States of America and all other countries, the expenses incident to said application listed on *Schedule A* to be borne and paid by said Assignees.

20.	C	₹.	200	S	
Date					

() Il		Kidt
R&D Biopharr	ηaceutic	als GmbH
Dr. Well	(cia)	Richter
Printed Name		
Mana	in	Director
Title	V	

20.	7.	2009
Date	•	,

Reighard Flech

20.7.2005

Manuela Richt

SCHEDULE A

Application Number	Filing Date	Inventor	Title	Ctry
10/535,474	May 17, 2005	Wolfgang Richter, et al.	THIA-EPOTHILONE DERIVATIVES FOR THE TREATMENT OF CANCER	US

63419(52171)